WALTHAM, Mass. — January 6, 2026 — Leads & Copy — Repligen Corporation (NASDAQ:RGEN) has announced the election of Dr. Martin D. Madaus as Chair of the Board, effective March 13, 2026. This follows the previously announced retirement of Tony Hunt from his role as Executive Chair and member of the Board of Directors, also effective March 13th. Hunt will continue to advise Repligen through March 2027.
Olivier Loeillot, President and CEO of Repligen, thanked Hunt for his service, highlighting his role in expanding the company’s portfolio of innovative products. Loeillot expressed confidence in Madaus’s leadership, citing his expertise in bioprocessing and biopharma.
Dr. Madaus expressed his gratitude for being elected Chair and commended Hunt on his tenure at Repligen. He looks forward to guiding Repligen towards future growth.
Hunt expressed pride in the company’s achievements during his leadership, emphasizing its clear strategy, disciplined execution, and dedicated team. He voiced confidence in Loeillot and Madaus to lead Repligen to continued success.
Dr. Madaus has been a director of Repligen since February 2023. His 36 years of industry experience include a tenure as Chairman, President, and CEO of Millipore Corporation, where he played a key role in the company’s transformation and its acquisition by Merck KGaA in 2010. Madaus currently serves on the boards of Azenta, Inc. and Hologic, Inc. He holds a D.V.M. from the University of Munich and a Ph.D. from the University of Veterinary Medicine of Hanover.
Repligen Corporation, a global life sciences company, develops and commercializes bioprocessing technologies and systems for manufacturing biological drugs. The company’s focus areas include Filtration and Fluid Management, Chromatography, Process Analytics, and Proteins. Repligen’s corporate headquarters are in Waltham, Massachusetts, with manufacturing sites primarily in the U.S., and additional sites in Estonia, France, Germany, Ireland, the Netherlands, and Sweden.
Repligen Contact:
Jacob Johnson
VP, Investor Relations
781-419-0204
investors@repligen.com
Source: Repligen Corporation
